Murray Stahl’s Intellia Therapeutics NTLA Stock Holding History

Murray Stahl’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Sell	12,584 -604	-5%	-$8.45K	﹤0.01%	295
2026 Q1	$169K	Sell	13,188 -604	-4%	-$7.69K	﹤0.01%	309
2025 Q4	$124K	Sell	13,792 -604	-4%	-$8.31K	﹤0.01%	309
2025 Q3	$249K	Buy	14,396 +604	+4%	+$7.44K	﹤0.01%	284
2025 Q2	$129K	Sell	13,792 -804	-6%	-$6.6K	﹤0.01%	327
2025 Q1	$104K	Buy	14,596 +200	+1%	+$2.02K	﹤0.01%	327
2024 Q4	$168K	Buy	14,396 +604	+4%	+$9.43K	﹤0.01%	320
2024 Q3	$283K	Sell	13,792 -604	-4%	-$13.9K	﹤0.01%	281
2024 Q2	$322K	Hold	14,396	–	–	0.01%	248
2024 Q1	$396K	Hold	14,396	–	–	0.01%	231
2023 Q4	$439K	Sell	14,396 -604	-4%	-$17.4K	0.01%	217
2023 Q3	$474K	Hold	15,000	–	–	0.01%	219
2023 Q2	$612K	Hold	15,000	–	–	0.01%	200
2023 Q1	$559K	Buy	15,000 +5,000	+50%	+$196K	0.01%	208
2022 Q4	$349K	Hold	10,000	–	–	0.01%	241
2022 Q3	$560K	Hold	10,000	–	–	0.01%	200
2022 Q2	$518K	Hold	10,000	–	–	0.01%	210
2022 Q1	$727K	Hold	10,000	–	–	0.01%	202
2021 Q4	$1.18M	Hold	10,000	–	–	0.03%	167
2021 Q3	$1.34M	Hold	10,000	–	–	0.03%	152
2021 Q2	$1.62M	Hold	10,000	–	–	0.03%	145
2021 Q1	$803K	Hold	10,000	–	–	0.02%	200
2020 Q4	$544K	Hold	10,000	–	–	0.02%	228
2020 Q3	$199K	Hold	10,000	–	–	0.01%	337
2020 Q2	$210K	Buy	+10,000	New	+$170K	0.01%	338

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Murray Stahl's NTLA Position: Q2 2026 in Review

Murray Stahl reduced its Intellia Therapeutics (NTLA) stake by 4.6% in Q2 2026, selling an estimated $8.45K and leaving 12,584 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #295.

Murray Stahl first reported a position in NTLA in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.62M in Q2 2021. 326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Murray Stahl held 12,584 shares of Intellia Therapeutics worth $213K as of Q2 2026.
Murray Stahl sold 604 Intellia Therapeutics shares in Q2 2026, an estimated $8.45K.
Intellia Therapeutics made up ﹤0.01% of Murray Stahl's portfolio in Q2 2026, its #295 holding.
Murray Stahl first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 25 quarters since.
Murray Stahl's Intellia Therapeutics position peaked at $1.62M in Q2 2021.
326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.